ISV President’s Message Linda S. Klavinskis, PhD (ISV President, 2024-2025) Professor of Viral Immunology, Department of Infectious Diseases, King’s College London. It is an honour and privilege to serve as President of the ISV, an association that brings together talented scientists from across the globe at all stages of their careers to exchange
Blog - In an historic moment for regional solidarity and leadership, West African Ministers of Health today pledged their joint commitment to advance the development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant threat to regional health security...
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode,Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell discuss promising advances in the field of HIV vaccine research and how we can prepare for optimal rollout of an eventual HIV vaccine.
Presenters:
Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics), MBE (Research Ethics), CIP Senior Principal Clinical Research Scientist Center for Microbiology Research KEMRI Research Professor Departments of Global Health and Obstetrics and Gynecology University of Washington, Nairobi, Kenya Seattle, Washington
Peter Godfrey-Faussett, MBBS, FRCP(UK) Science Advisor United Nations Joint Programme on HIV (UNAIDS) Professor of Infectious Diseases and International Health London School of Hygiene and Tropical Medicine London, United Kingdom
Nina Russell, MD Director for TB and HIV Prevention Bill & Melinda Gates Foundation Seattle, Washington
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine.
Presenters:
Susan Buchbinder, MD Clinical Professor Departments of Medicine, Epidemiology and Biostatistics University of California, San Francisco Director, Bridge HIV San Francisco Department of Public Health San Francisco, California
Jontraye Davis, MHA, PMD Pro Community Program Manager FHI 360 Adjunct Instructor North Carolina Central University Durham, North Carolina
Special Commentator:
Jerome H. Kim, MD Director General International Vaccine Institute Seoul, South Korea
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Broad-spectrum vaccines have been proposed as a tool for rapid response to emerging infectious disease threats and are in pre-clinical development. Here, the authors use mathematical modelling to assess the potential impacts of broadly protective sarbecovirus vaccines for a hypothetical “SARS-X”...
A trial has begun in Poland of 45 doctors who spread anti-vaccine claims during the Covid-19 pandemic. If found guilty of disseminating information inconsistent with medical knowledge, they could lose their medical licences. The doctors are part of a group, the Polish Association of Independent Physicians and Scientists (PSNLiN), that actively opposes the use of vaccines. “They signed a letter which falsely presented both the results of research on vaccines and the entire strategy to combat the pandemic,” Paweł Wróblewski, president of the Lower Silesian Medical Chamber, which is overseeing the case, told broadcaster TVN. “The doctors are accused of promoting anti-health attitudes and publicly disseminating information that is inconsistent with current medical knowledge, thereby acting to the detriment of patients and the entire society,” he added.
Press Release - Gavi and IRC's REACH consortium administered 9 million vaccine doses, protecting against diseases such as measles and diphtheria Consortium negotiates access to reach 96% of communities in hard-to-reach areas across the region Conflict, displacement and climate-driven droughts continue...
This report describes interim 2024–2025 seasonal flu vaccine effectiveness estimates in outpatient settings and against flu-associated hospitalizations.
Background Vaccine hesitancy, the delay in acceptance or reluctance to vaccinate, ranks among the top threats to global health. Identifying modifiable factors contributing to vaccine hesitancy is crucial for developing targeted interventions to increase vaccination uptake.
Background There are increasing reports of outbreaks of measles in countries that achieved measles elimination using two doses of measles-mumps-rubella (MMR) vaccine, particularly in health care settings.
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Swati Gupta and Mr. Marc Dixneuf discuss how to broaden global advocacy and increase investment for an HIV vaccine.
Presenters:
Swati Gupta, DrPH, MPH Vice President and Head of Emerging Infectious Diseases and Scientific Strategy International AIDS Vaccine Initiative New York, New York
Marc Dixneuf, PhD Director General AIDES Pantin, France
Special Commentator:
Jonathan Weber, MB, BChir, PhD, FRCP, FRCPath, FMed Sci Dean of the Faculty of Medicine Imperial College London, United Kingdom
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this first episode, Dr. Linda-Gail Bekker and Ms. Maureen Luba discuss why an HIV vaccine remains the ultimate game-changer to ending the epidemic and the gaps it will address in the expanding HIV prevention landscape.
Presenters:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Chief Operating Officer Desmond Tutu HIV Foundation Deputy Director Desmond Tutu HIV Centre Past President International AIDS Society Faculty of Health Sciences University of Cape Town Cape Town, South Africa
Maureen Luba Africa Region Advocacy Advisor Global Advocacy for HIV Prevention AIDS Vaccine Advocacy Coalition
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Vaccines provide one of the most reliable defenses against infectious diseases. By stimulating the body’s immune system to recognize and fight off harmful pathogens, they create a protective barrier long before exposure occurs.
People who whistle past the graveyard (of vaccines) to assure themselves the RFK Jr,. won't take away their vaccines are deluding themselves. It's on video!
A greater weight must be placed on vaccine manufacturing and distribution, both in the United States and worldwide, as we saw major imbalances in the world's response to Covid-19 that highlighted gaps in accessibility.
A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022.The study evaluated vaccine-related reactions in a predominantly dengue-naïve population, highlighting the importance of post-marketing...
Author summary Escherichia coli is the primary cause of urinary tract infections. Adherence to uroepithelial surfaces is mediated by the pilus adhesin protein FimH, which is of interest as a vaccine candidate.
Thanks to cutting edge research at NDM's Jenner Institute and Oxford University Clinical Research Unit (OUCRU), Oxford remains at the forefront of research to develop new vaccines to protect against this devastating disease.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
![Disrupted US vaccine meetings could threaten timelines, access and transparency around [flu] shots | International Society for Vaccines | Scoop.it](https://img.scoop.it/2PkXlUcVO6vGM8aAWJk88Dl72eJkfbmt4t8yenImKBVvK0kTmF0xjctABnaLJIm9)
